Physician profile
Mukesh Bhatt
NPI 1326026154
$6,529.00
in general payments reported to CMS, 2019-2025
56 companies · $1,271 in 2025
The $1,271 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $177 · 2021: $779 · 2022: $1,405 · 2023: $1,070 · 2024: $1,351 · 2025: $1,271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,546 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,545.84 |
| Education | $145.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $692.85 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $372.08 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $324.70 | 2019-2025 | Calquence, Tagrisso, Enhertu |
| Abbvie INC. | $318.01 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $302.48 | 2021-2025 | Keytruda, Welireg, Reblozyl |
| Janssen Biotech, INC. | $288.94 | 2021-2025 | Rybrevant, Imbruvica |
| Celgene Corporation | $259.77 | 2019-2025 | Reblozyl, Pomalyst, Pomalyst |
| Genzyme Corporation | $255.83 | 2019-2025 | |
| Lilly USA, LLC | $212.19 | 2019-2025 | Retevmo, Jaypirca, Verzenio |
| Regeneron Healthcare Solutions, INC. | $200.51 | 2022-2025 | Libtayo, Lynozyfic |
| Daiichi Sankyo INC. | $191.68 | 2020-2025 | Enhertu |
| Incyte Corporation | $177.99 | 2021-2025 | Jakafi, Niktimvo, Monjuvi |
| Aveo Pharmaceuticals, INC. | $174.42 | 2022-2025 | Fotivda |
| Pfizer INC. | $173.58 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.62 | 2020-2025 | Gilotrif |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $145.23 | 2019-2025 | Tecentriq, Venclexta, Tecentriq Hybreza |
| Pharmacyclics LLC, An Abbvie Company | $136.13 | 2020-2023 | Imbruvica |
| Gilead Sciences, INC. | $134.20 | 2019-2025 | Trodelvy |
| Astellas Pharma US INC | $130.94 | 2022-2025 | Vyloy, Xospata, Xtandi |
| Ipsen Biopharmaceuticals, INC | $116.69 | 2021-2025 | Onivyde, Somatuline Depot |
| Seagen INC. | $115.41 | 2019-2023 | Adcetris |
| Amgen INC. | $113.52 | 2019-2023 | Lumakras |
| Bayer Healthcare Pharmaceuticals INC. | $113.10 | 2020-2024 | |
| Boston Scientific Corporation | $110.80 | 2019 | |
| Beigene USA, INC. | $102.91 | 2020-2025 | Brukinsa, Tevimbra |
| Rigel Pharmaceuticals, INC. | $89.00 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Adc Therapeutics America, INC. | $88.55 | 2022-2025 | |
| Morphosys, US INC. | $81.41 | 2021-2023 | Monjuvi |
| Eusa Pharma (US) LLC | $67.11 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.72 | 2019-2025 | Fruzaqla |
| Eisai INC. | $58.69 | 2022-2025 | |
| Exelixis INC. | $57.75 | 2023-2025 | Cabometyx |
| Jazz Pharmaceuticals INC. | $56.70 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $53.28 | 2022-2025 | Ultomiris |
| Blueprint Medicines Corporation | $52.33 | 2021-2023 | Ayvakit |
| Coherus Oncology, INC. | $48.36 | 2020-2021 | |
| Tersera Therapeutics LLC | $44.12 | 2019 | |
| Blue Earth Diagnostics | $37.05 | 2021-2022 | |
| Emd Serono, INC. | $35.81 | 2022-2025 | |
| Epizyme, INC. | $34.02 | 2021-2022 | |
| Taiho Oncology, INC. | $32.99 | 2023-2024 | |
| Coloplast Corp | $30.18 | 2019 | |
| Adaptive Biotechnologies Corporation | $30.07 | 2022-2023 | Clonoseq |
| Myovant Sciences INC. | $27.92 | 2021 | |
| Tempus Ai, INC | $27.91 | 2024 | |
| Kite Pharma, INC. | $27.66 | 2021-2022 | |
| Beone Medicines USA, INC. | $23.70 | 2025 | Brukinsa |
| Agios Pharmaceuticals, INC. | $23.33 | 2025 | Pyrukynd |
| Glaxosmithkline, LLC. | $20.15 | 2022 | |
| Genmab U.S., INC. | $19.13 | 2025 | Epkinly |
| Geron Corporation | $17.99 | 2025 | Rytelo |
| Puma Biotechnology, INC. | $16.12 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $15.79 | 2022 | |
| Springworks Therapeutics, INC. | $15.09 | 2025 | Gomekli |
| Mirati Therapeutics, INC. | $13.99 | 2024 | Krazati |
| Clovis Oncology, INC. | $10.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mukesh Bhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.